Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 14, 2015 10:30 ET | Source: Amarantus BioScience Holdings, Inc.

Past President of the American Burn Association Dr. David Ahrenholz Provides Video Interview on Potential of ESS for Treatment of Severe Burns

SAN FRANCISCO and GENEVA, Oct. 14, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in...
October 08, 2015 08:33 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus

- Single ESS Treatment Provided Successful Skin Replacement on Infant Patient, Supporting Natural Skin Growth That Required no Additional Grafts or Reconstructive Surgery - Data Provides...
October 06, 2015 08:30 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Publication of Study on Targeted Delivery of MANF to Brain Areas Associated With Parkinson's Disease

- Renishaw plc’s convection-enhanced delivery device results in accurate targeting and distribution of MANF to Parkinson’s disease-associated brain areas - - Study confirms the potential of...
October 05, 2015 10:47 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus to Present at the 2015 Aegis Growth Conference

SAN FRANCISCO and GENEVA, Oct. 05, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in...
October 01, 2015 09:25 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus to Focus Near-Term Development Efforts on Engineered Skin Substitute for Indications in Rare Pediatric Diseases

Company is Currently Evaluating Human Clinical Data From Previous Studies Supporting Clinical Development Program Expansion Beyond Treatment of Adult Burns Into Pediatric Burns Published Data...
October 01, 2015 07:32 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Closes $5.5 Million Capital Infusion Through the Issuance of a Combination of Preferred Stock and Secured Debt Convertible

SAN FRANCISCO and GENEVA, Oct. 1, 2015 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates for orphan...
September 14, 2015 10:30 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Receives Orphan Drug Designation From the U.S. Food and Drug Administration for MANF for the Treatment of Retinal Artery Occlusion

SAN FRANCISCO and GENEVA, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in...
September 03, 2015 07:05 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Results of Annual Meeting

SAN FRANCISCO and GENEVA, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
August 26, 2015 12:30 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Moves Annual Meeting Date Forward to September 2, 2015

SAN FRANCISCO and GENEVA, Aug. 26, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...
August 20, 2015 08:35 ET | Source: Amarantus BioScience Holdings, Inc.

Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Product Candidate MANF

SAN FRANCISCO and GENEVA, Aug. 20, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing therapeutic and diagnostic product candidates in orphan...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right